A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE

Starting soon · Phase 3 · Has a placebo group

Conditions studied: Developmental and Epileptic Encephalopathy (DEE)

In brief

The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC). The current JZP926-303 study is being conducted to evaluate the safety and efficacy of CBD-OS in participants with Developmental and Epileptic Encephalopathy (DEE).

Key facts

Study ID

NCT07723976

Run by

Jazz Pharmaceuticals

People needed

120

Starts

2026-10-30

Expected to finish

2029-09-04

Last updated by the study team

2026-07-24

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.